9-hydroxy-6H-pyrido<3,4-b>carbazole | 60189-36-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 9-hydroxy-6H-pyrido<3,4-b>carbazole
• 英文别名: 6H-pyrido[4,3-b]carbazol-9-ol
• CAS: 60189-36-8
• 化学式: C₁₅H₁₀N₂O
• 分子量: 234.257
• InChiKey: OUKTWOHHYIUEAM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  48.9
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-氯甲基咪唑啉盐酸盐 、 9-hydroxy-6H-pyrido<3,4-b>carbazole 在 sodium iodide 、 sodium hydroxide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成 9-((4,5-dihydro-1H-imidazol-2-yl)methoxy)-6H-pyrido[4,3-b]carbazole
  参考文献：
  名称：

  [EN] SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS
  [FR] PETITES MOLÉCULES CIBLANT L'ARN PROVOQUANT LA SLA

  摘要：

  本文披露了一些化合物，这些化合物能选择性地结合扩增的转录重复r(G4C2)exp，防止RNA结合蛋白的封存，并抑制与重复相关的非ATG（RAN）翻译，从而负责生成毒性二肽重复，导致包括肌萎缩侧索硬化症（ALS）和额颞叶痴呆（FTD）在内的疾病。这些化合物及其药物组合物对治疗由扩增的G4C2重复RNA（r(G4C2)exp）特征的疾病或状况，如ALS和FTD，具有用处。

  公开号：

  WO2022055922A1
• 作为产物：
  描述：

  1-苄基-4-(1-吡咯烷基)-1,2,3,6-四氢吡啶 在 盐酸 、 palladium 10% on activated carbon 、 氢气 作用下， 以 1,4-二氧六环 、 二苯醚 、 乙醇 、 乙酸乙酯 为溶剂， 20.0~100.0 ℃ 、103.42 kPa 条件下， 反应 25.0h， 生成 9-hydroxy-6H-pyrido<3,4-b>carbazole
  参考文献：
  名称：

  [EN] SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS
  [FR] PETITES MOLÉCULES CIBLANT L'ARN PROVOQUANT LA SLA

  摘要：

  本文披露了一些化合物，这些化合物能选择性地结合扩增的转录重复r(G4C2)exp，防止RNA结合蛋白的封存，并抑制与重复相关的非ATG（RAN）翻译，从而负责生成毒性二肽重复，导致包括肌萎缩侧索硬化症（ALS）和额颞叶痴呆（FTD）在内的疾病。这些化合物及其药物组合物对治疗由扩增的G4C2重复RNA（r(G4C2)exp）特征的疾病或状况，如ALS和FTD，具有用处。

  公开号：

  WO2022055922A1

文献信息

• Synthesis and biological properties of some 6H-pyrido[4,3-b]carbazoles
  作者：Sydney Archer、Bruce S. Ross、Livia Pica-Mattoccia、Donato Cioli

  DOI：10.1021/jm00390a014

  日期：1987.7

  The effect of methyl substitution on the biological properties of the ellipticines was reexamined. 9-Hydroxy-6H-pyrido[4,3-b]carbazole was synthesized and shown to be devoid of antitumor activity in murine P388 lymphocytic leukemia in mice. 5-(Hydroxymethyl)-11-methyl-6H-pyrido[4,3-b]carbazole (46) and its N-methylcarbamate (48) were synthesized and their effect on macromolecular synthesis in HeLa cells

  重新检查了甲基取代对玫瑰树碱生物学特性的影响。合成了9-羟基-6H-吡啶并[4,3-b]咔唑，在小鼠P388淋巴细胞白血病中没有抗肿瘤活性。合成了5-（羟甲基）-11-甲基-6H-吡啶并[4,3-b]咔唑（46）及其N-甲基氨基甲酸酯（48），并比较了它们对HeLa细胞中大分子合成的影响及其抗肿瘤特性。玫瑰树碱的那些。与生物碱1和羟甲基衍生物46产生部分可逆的[3H]胸苷掺入抑制作用相比，氨基甲酸酯不可逆地阻止了ti化嘧啶的掺入。该酯在P388淋巴细胞白血病中也比1或46更有效。
• Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto
  申请人：EMORY UNIVERSITY

  公开号：US10434220B2

  公开（公告）日：2019-10-08

  The disclosure relates to compounds and compositions for bone formation, fracture treatment, bone grafting, bone fusion, cartilage maintenance and repair, and methods related thereto. In certain embodiments, the disclosure relates to compositions comprising one or more compound(s) disclosed herein derivatives, or salt thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement. In certain embodiments, compounds disclosed herein are useful for managing obesity and diabetes or other metabolic syndromes by modulation of brown fat.

  本公开涉及用于骨形成、骨折治疗、骨移植、骨融合、软骨维护和修复的化合物和组合物，以及与之相关的方法。在某些实施方案中，本公开涉及包含一种或多种本文公开的化合物衍生物或其盐的组合物，用于骨生长过程。在一个典型的实施方案中，骨移植组合物被植入受试者所需骨生长或增强的部位。在某些实施方案中，本文公开的化合物可通过调节棕色脂肪来控制肥胖和糖尿病或其他代谢综合征。
• ARCHER, S.;ROSS, B. S.;PICA-MATTOCCIA, L.;CIOLI, D., J. MED. CHEM., 30,(1987) N 7, 1204-1210
  作者：ARCHER, S.、ROSS, B. S.、PICA-MATTOCCIA, L.、CIOLI, D.

  DOI：——

  日期：——
• BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO
  申请人：EMORY UNIVERSITY

  公开号：US20150148292A1

  公开（公告）日：2015-05-28

  The disclosure relates to compounds and compositions for bone formation, fracture treatment, bone grafting, bone fusion, cartilage maintenance and repair, and methods related thereto. In certain embodiments, the disclosure relates to compositions comprising one or more compound(s) disclosed herein, such as 2-(2-Methoxybenzylidene)-1-indan-one; N-(4-arsonophenyl)glycine; 1,2-Benzenedicarboxylic acid, 1-(1-methylheptyl)ester; (4′-hydroxybiphenyl-4-yl) (phenyl)methanone; 2,2-dimethylchroman-6-carboxylic acid, (4,7-dihydroxy-8-methyl-2-oxo-2H-chromen-3-yl)amide; Ethyl 2-((4-chlorophenyl)thio)-1,3-benzothiazol-6-yl carbamate; Ethyl (2-(azepan-1-yl)benzo[d]thiazol-6-yl) carbamate; Porfiromycin; 1,3-benzodioxol-5-yl-[4-(3,4,5-trimethoxybenzoyl)-3-furyl]methanone; Tricinolone acetophenonide; 2,4-bis(3,4-dimethoxyphenyl)-4H-pyrano[3,2-c]chromen-5-one; Methyl 5-fluoro-4-methoxy-2,6-dioxohexahydro-5-pyrimidine carboxylate; 5-(naphthalen-1-yl)-1-phenyl-1h-tetrazole; 5-(2-phenylquinolin-4-yl)-1,3,4-oxadiazol-2-ol; N-[2,4,5-trimethyl-4-(trichloromethyl)cyclohexa-2,5-dien-1-ylidene]hydroxylamine; 4-benzoyl-3,4-dihydro-Benzo[f]quinoline-3-carbonitrile; 2-nitro-3-phenylspiro[cyclopropane-1,9′-fluorene]; 3-[4-(furan-2-ylmethyl)-5-sulfanylidene-1,2,4-dithiazolidin-3-ylidene]-1,1-dimethyl-thiourea; (6-acetamido-7-methyl-5,8-dioxo-2,3-dihydro-1H-pyrrolo[1,2-a]benzimidazol-3-yl)2-methoxyacetate; 5-Iodo-1H-indole-2,3-dione; 4,5-dihydro-1,2,9,10-tetramethoxy dibenzo[de,g]quinoline-6-carboxylic acid, ethyl ester; [2,6-bis(2,4-dimethylphenyl)-4-(2-methoxyacetyl)oxy-phenyl]2-methoxyacetate; 5,11-dimethyl-2-(2-piperidin-1-ylethyl)-6H-pyrido[4,3-b]carbazol-2-ium-9-ol; 2-[3-[[4-[(3-nitroacridin-9-yl)amino]phenyl]sulfamoyl]propyl]guanidine; 1-[[2-(dimethylamino)ethyl]amino]-7-hydroxy-4-methyl-9H-thioxanthen-9-one; 5-amino-1H-1,2,4-triazole-3-carboxylic acid, methyl ester; methyl N-cyano-N′-prop-2-en-1-ylcarbamimidothioate; 5,7-dinitro-8-quinolinol; 5-nitrosoquinolin-8-ol; Cantharidin; 1,7-Diaminoacridine; 3-Methyl-3-(1-naphthyl)-2-benzofuran-1(3H)-one; Dichlorolapachol; Lycobetaine; 6-(1-aziridinyl)-2,3-dihydro-3-(propionyl)-7-methyl-1H-Pyrrolo[1,8]-dione; 4-Nitroestrone 3-methyl ether; 5,11-dimethyl-6H-pyrido[4,3-b]carbazole-1-carboxamide hydrochloride; 5-Methoxysterigmatocysin; (6-acetamido-7-methyl-5,8-dioxo-2,3-dihydro-1H-pyrrolo[1,2-a]benzimidazol-3-yl)2-methoxyacetate; Horminon; 7′,8′-dimethyl-2′-oxo-4′,4a′,6a′,7′-tetrahydro-2′H-spiro[oxirane-2,1′-pentaleno[1,6a-c]pyran]-5′-carboxylate; Nybomycin acetate; 5H-[1,6]indeno[1,2-c]isoquinoline-5,12-dione; 2,3-dimethoxy-6-methyl-Nitidine; Iproplatin; 3-[(deoxyhexosyl)oxy]-2-(3,4-di-hydroxyphenyl)-6,8-dihdroxy-4H-1-Benzopyran-4-one; 2-O-benzyl 8-O-methyl 3-(4-methylphenyl)sulfonyl-4,5-dioxo-6H-pyrrolo[3,2-e]indole-2,8-dicarboxylate; 6-bromo-5,8-dihydroxy-7-[4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl]naphthalene-1,4-dione; 5-methylbenzo[c]phenanthridin-5-ium-2,3,8,9-tetrol; (6-acetyl-4-oxo-1,3-diphenyl-2-sulfanylidenethieno[2,3-d]pyrimidin-5-yl)-2,4-dichlorobenzoate; N—[C-[4-[bis(2-cyanoethyl)amino]-2-methylphenyl]-N-(4-methylanilino)carbonimidoyl]imino-4-methylbenzamide; Gelcohol; Curcumin; Tirandamycin; Noscapine; Aristolochic acid; Himbacine; Fumagillin; Fumitremorgin C; Physalin B; derivatives, or salt thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement. In certain embodiments, compounds disclosed herein are useful for managing obesity and diabetes or other metabolic syndromes by modulation of brown fat.
• US4483989A
  申请人：——

  公开号：US4483989A

  公开（公告）日：1984-11-20